Adoptive transfer of pTRP2-specific CTLs expanding by bead-based artificial antigen-presenting cells mediates anti-melanoma response

Cancer Letters

Volumn 271, Issue 1, 2008, Pages 129-139

  Lu, Xiaoling ^a   Jiang, Xiaobing ^b   Liu, Ruen ^c   Zhao, Hongyang ^b   Liang, Zhihui ^b  

^a HUAZHONG UNIVERSITY OF SCIENCE AND TECHNOLOGY   (China)

^b HUAZHONG UNIVERSITY OF SCIENCE AND TECHNOLOGY   (China)

^c CHINA JAPAN FRIENDSHIP HOSPITAL   (China)

Author keywords

aAPCs; Cytotoxic T lymphocytes; Dimer; Malignant melanoma

Indexed keywords

CD137 LIGAND; CD28 ANTIGEN; CD8 ANTIGEN; CD83 ANTIGEN; DIMER; IMMUNOGLOBULIN; LATEX; MAJOR HISTOCOMPATIBILITY ANTIGEN; MONOCLONAL ANTIBODY; MONOCLONAL ANTIBODY Y3; TYROSINASE RELATED PROTEIN 2; UNCLASSIFIED DRUG;

ADOPTIVE TRANSFER; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIGEN PRESENTING CELL; ARTICLE; CANCER CELL CULTURE; CANCER IMMUNOTHERAPY; CD8+ T LYMPHOCYTE; COMPLEX FORMATION; CONTROLLED STUDY; CYTOLYSIS; CYTOTOXIC T LYMPHOCYTE; FEMALE; IMMUNE RESPONSE; IN VITRO STUDY; LUNG METASTASIS; MELANOMA; MELANOMA CELL; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION;

ADOPTIVE TRANSFER; ANIMALS; ANTIBODIES, MONOCLONAL; ANTIGEN-PRESENTING CELLS; COCULTURE TECHNIQUES; ENZYME-LINKED IMMUNOSORBENT ASSAY; FEMALE; INTRAMOLECULAR OXIDOREDUCTASES; MELANOMA; MICE; MICE, INBRED C57BL; T-LYMPHOCYTES, CYTOTOXIC;

MURINAE;

EID: 53049110735     PISSN: 03043835     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.canlet.2008.05.049     Document Type: Article

References (49)

1. Melief C.J., and Kast W.M. T cell immunotherapy of tumors by adoptive transfer of cytotoxic T lymphocytes and by vaccination with minimal essential epitopes. Immunol. Rev. 145 (1995) 167-177
2. Riddell S.R., and Greenberg P.D. Principles for adoptive T cell therapy of human viral diseases. Annu. Rev. Immunol. 13 (1995) 545-586
3. Meidenbauer N., Marienhagen J., Laumer M., et al. Survival and tumor localization of adoptively transferred melan-a-specific T cells in melanoma patients. J. Immunol. 170 (2003) 2161-2169
4. Mackensen A., Herbst B., Chen J.L., et al. Phase I study in melanoma patients of a vaccine with peptide-pulsed dendritic cells generated in vitro from CD34(+) hematopoietic progenitor cells. Int. J. Cancer 86 (2000) 385-392
5. + melan-A-specific cytotoxic T lymphocytes for adoptive transfer in tumor immunotherapy. Clin. Cancer Res. 6 (2000) 1997-2005
6. Santin A.D., Bellone S., Ravaggi A., et al. Induction of tumour-specific CD8(+) cytotoxic T lymphocytes by tumour lysate-pulsed autologous dendritic cells in patients with uterine serous papillary cancer. Br. J. Cancer 86 (2002) 151-157
7. + cytotoxic T lymphocytes from patients with locally advanced breast cancer by tumor antigen-pulsed autologous dendritic cells. J. Surg. Res. 112 (2003) 189-197
8. Ratta M., Fagnoni F., Cuti A., et al. Dendritic cells are functionally defective in multiple myeloma: the role of interleukin-6. Blood 100 (2002) 230-237
9. Ruffini P.A., and Kwak L.W. Immunotherapy of multiple myeloma. Semin. Hematol. 38 (2001) 260-267
10. Zheng C., Ostad M., Andersson M., et al. Natural cytotoxicity to autologous antigen-pulsed dendritic cells in multiple myeloma. Br. J. Haematol. 118 (2002) 778-785
11. Della Bella S., Gennaro M., Vaccari M., et al. Altered maturation of peripheral blood dendritic cells in patients with breast cancer. Br. J. Cancer 89 (2003) 1463-1472
12. Jiang X.B., Lu X.L., Liu R.E., et al. HLA tetramer-based artificial antigen-presenting cells efficiently stimulate cytotoxic T lymphocytes specific for malignant glioma. Clin. Cancer Res. 13 (2007) 7329-7334
13. van Rensen A.J., Wauben M.H., Grosfeld-Stulemeyer M.C., et al. Liposomes with incorporated MHC class II/peptide complexes as antigen presenting vesicles for specific T cell activation. Pharm. Res. 16 (1999) 198-204
14. Prakken B., Wauben M., Genini D., et al. Artificial antigen-presenting cells as a tool to exploit the immune 'synapse'. Nat. Med. 6 (2000) 1406-1410
15. Curtsinger J., Deeths M.J., Pease P., et al. Artificial cell surface constructs for studying receptor-ligand contributions to lymphocyte activation. J. Immunol. Methods 209 (1997) 47-57
16. Tham E.L., Jensen P.L., and Mescher M.F. Activation of antigen-specific T cells by artificial cell constructs having immobilized multimeric peptide-class I complexes and recombinant B7-Fc proteins. J. Immunol. Methods 249 (2001) 111-119
17. Maus M.V., Riley J.L., Kwok W.W., et al. Clin. Immunol. 106 (2003) 16-22
18. Oelke M., Maus M.V., Didiano D., et al. Ex vivo induction and expansion of antigen-specific cytotoxic T cells by HLA-Ig-coated artificial antigen-presenting cells. Nat. Med. 9 (2003) 619-624
19. + lymphocytes for adoptive therapy generated using an artificial antigen-presenting cell. Clin. Cancer Res. 13 (2007) 1857-1867
20. Bloom M.B., Perry-Lalley D., Robbins P.F., et al. Identification of tyrosinase-related protein 2 as a tumor rejection antigen for the B16 melanoma. J. Exp. Med. 185 (1997) 453-459
21. Schreurs M.W., Eggert A.A., de Boer A.J., et al. Dendritic cells break tolerance and induce protective immunity against a melanocyte differentiation antigen in an autologous melanoma model. Cancer Res. 60 (2000) 6995-7001
22. Yang Y., Fruh K., and Chambers J. Major histocompatibility complex (MHC) encoded HAM2 is necessary for antigenic peptide loading onto class I MHC molecules. J. Biol. Chem. 276 (1992) 11669-11672
23. Townsend A.R.M., Ohlen C., Bastin J., et al. Association of class I major histocompatibility heavy and light chains induced by viral peptides. Nature 340 (1989) 443-448
24. Mandelboim O., Berke G., Fridkin M., et al. CTL induction by a tumor-associated antigen octapeptide derived from a murine lung carcinoma. Nature 369 (1994) 67-71
25. Altman J.D., Moss P.A., Goulder P.J., et al. Henotypic analysis of antigen-specific T lymphocyte. Science 274 (1996) 94-96
26. Lu X.L., Jiang X.B., Liu R.E., et al. Generation of allo-restricted cytotoxic T lymphocytes against malignant glioma by artificial antigen-presenting cells. Cancer Lett. 256 (2007) 128-135
27. + T cell responses in vivo and in vitro. Proc. Natl. Acad. Sci. USA 96 (1999) 9781-9786
28. Qian L., and Qian G.X. In vivo CTL immunity can be elicited by OVA-linker-β2m fusion protein. Acta Biochim. Biophys. Sin. 34 (2002) 547-552
29. b antigens determined with monoclonal antibodies and H-2 mutant mice. Proc. Natl. Acad. Sci. USA 79 (1982) 4737-4741
30. Rosanberg SA., Yannelli J.R., Yang J.C., et al. Treatment of patients with metastatic melanoma with autologous tumor-infiltrating lymphocytes and interlaukin 2 [see comments]. J. Nat/Cancer Inst. 86 (1994) 1159-1166 (see comments)
31. Ogg G.S., Jin X., Bonhoeffer S., et al. Quantitation of HIV-1-specific cytotoxic T lymphocytes and plasma load of viral RNA. Science 279 (1998) 2103-2106
32. Busch D.H., Pilip I.M., Vijh S., et al. Coordinate regulation of complex T cell populations responding to bacterial infection. Immunity 8 (1998) 353-362
33. Romero P., Dunbar P.R., Valmori D., et al. Ex vivo staining of metastatic lymph nodes by class I major histocompatibility complex tetramers reveals high numbers of antigen-experienced tumor-specific cytolytic T lymphocytes. J. Exp. Med. 188 (1998) 1641-1650
34. Dunbar P.R., Ogg G.S., Chen J., et al. Direct isolation, phenotyping and cloning of low-frequency antigen-specific cytotoxic T lymphocytes from peripheral blood. Curr. Biol. 8 (1998) 413-416
35. + T cells from HIV-1-infected donors after CD3/CD28 costimulation. J. Hematother 7 (1998) 437-448
36. + T cells. Eur. J. Immunol. 27 (1997) 598-608
37. Oelke M., Maus M.V., Didiano D., et al. Nat. Med. 9 (2003) 619-625
38. Zemon H. An artificial solution for adoptive immunotherapy. Trends Biotechnol. 21 (2003) 418-420
39. Cheuk A.T., Mufti G.J., and Guinn B.A. Role of 4-1BB:4-1BB ligand in cancer immunotherapy. Cancer Gene Ther. 11 (2004) 215-226
40. + T cell proliferation and lead to the amplification in vivo of cytotoxic T cell responses. J. Exp. Med. 186 (1997) 47-55
41. Cannons J.L., Lau P., Ghumman B., et al. 4-1BB ligand induces cell division, sustains survival, and enhances effector function of CD4 and CD8 T cells with similar efficacy. J. Immunol. 167 (2001) 1313-1324
42. Laderach D., Movassagh M., Johnson A., et al. 4-1BB co-stimulation enhances human CD8(+) T cell priming by augmenting the proliferation and survival of effector CD8(+) T cells. Int. Immunol. 14 (2002) 1155-1167
43. Kim J.A., Averbook B.J., Chambers K., et al. Cancer Res. 61 (2001) 2031-2037
44. Wiethe C., Dittmar K., Doan T., et al. Provision of 4-1BB ligand enhances effector and memory CTL responses generated by immunization with dendritic cells expressing a human tumor-associated antigen. J. Immunol. 170 (2003) 2912-2922
45. Yan X., Johnson B.D., and Orentas R.J. Murine CD8 lymphocyte expansion in vitro by artificial antigen-presenting cells expressing CD137L (4-1BBL) is superior to CD28, and CD137L expressed on neuroblastoma expands CD8 tumour-reactive effector cells in vivo. Immunology 112 (2004) 105-116
46. Bukczynski J., Wen T., and Watts T.H. Costimulation of human CD28-T cells by 4-1BB ligand. Eur. J. Immunol. 33 (2003) 446-454
47. Melero I., Bach N., Hellstrom K.E., et al. Amplification of tumor immunity by gene transfer of the co-stimulatory 4-1BB ligand: synergy with the CD28 co-stimulatory pathway. Eur. J. Immunol. 28 (1998) 1116-1121
48. Guinn B.A., Bertram E.M., DeBenedette M.A., et al. 4-1BBL enhances anti-tumor responses in the presence or absence of CD28 but CD28 is required for protective immunity against parental tumors. Cell. Immunol. 210 (2001) 56-65
49. + T cells and preferential enrichment for antigen specificity. Blood 107 (2006) 1528-1536